European Union and USA Veterinary Drug Development Online Training Course, June 21-25, 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Working Through Veterinary Drug Development in the EU (European Union) and USA Training Course" conference has been added to ResearchAndMarkets.com's offering.

This intensive five-day course provides a thorough understanding of how to develop a veterinary medicine in the EU and USA.

The development of veterinary medicine is complex, time-consuming and expensive. It requires teamwork from individuals with different scientific training and a wide range of skills.

Everyone involved must be aware of the main stages in the development programme and be able to relate his or her responsibilities to the expertise and needs of the scientists and commercial members of the team.

Furthermore, different approaches taken by the regulatory authorities in the EU and the USA mean that a comprehensive development programme must be designed in order for the product to be commercialised in both regions.

The event has been designed to demonstrate how pharmaceutical, pharmacological, toxicological and clinical investigations and regulatory management are brought together in the development programme. It will take participants through all the stages in the development of a veterinary medicinal product for which marketing authorisation is sought in the EU and the USA.

Presentations will cover pharmaceutical and process development, toxicological, pharmacological, residues and environmental studies, safety risk assessments, clinical development, regulatory and marketing input and project management.

Gain a comprehensive understanding of the processes for the EU and USA, including:

• EU and US regulatory frameworks, strategies and procedures n MRLs Parts A & B; MAA Parts IIIA & IIIB
• US FDA approach to HFS studies
• User safety risk assessment in the EU
• Planning pre-clinical and clinical development
• Environmental risk assessment Phases I and II n EU and US target animal safety
• Minor use and minor species (MUMS)
• Writing and managing regulatory submissions

Who Should Attend:

This course has been designed for anyone who has limited experience in only one of the disciplines in veterinary medicine development, such as pharmaceutical or analytical development, clinical trials, regulatory affairs or quality assurance. Anyone learning the role of project manager, as well as more experienced personnel seeking to review special problems encountered in product development, will benefit from the comprehensive programme delivered by experienced professionals.

Previous delegates who have benefited from this course include clinical scientists, pharmaceutical scientists, marketing managers and personnel from regulatory affairs, R&D and development.

Key Topics Covered:

Day 1 09:00 - 15:00 UK/London

EU regulatory framework for regulation of veterinary medicines

• What is the EU?
• EU legal framework for regulation of veterinary medicines
• Legal base of procedures and data requirements

US regulatory framework for regulation of veterinary drugs

• Current governing laws and regulations
• Federal agency jurisdictions

EU and USA: differences and similarities

• INAD and NAD in the USA
• Phased submission in USA vs marketing authorisation application in EU
• EU MRLs vs US HFS section
• EU renewal, variations, extensions vs US supplements
• EU certificate of suitability and EDMFs vs US DMFs
• Different requirements for user safety and environmental risk assessments

The global development programmes

• Requirements for EU
• Requirements for the USA
• Achieving a global development programme

USA regulatory strategies and procedures

• Applications for NCEs and supplements
• Generic drug applications

EU regulatory strategies and procedures

• Full and abbreviated applications
• Generic applications
• Centralised procedure
• Decentralised, MRP and national procedures

Day 2 09:00 - 15:15 UK/London

MRLs Part A safety and MAA Part IIIA

• The toxicological data requirements
• Determining the NOEL and ADI

USA FDA approach to HFS studies

• Toxicology studies
• Margins of safety

MRLs Part B residues and MAA Part IIIB

• 'Hot' and 'cold' residue studies
• How to determine maximum residue limits
• Analytical methods for residues
• Determining the withdrawal period

FDA evaluation of consumer safety

• Human food technical safety section
• Residue issues

Workshop - session 1

Day 3 09:00 - 14:45 UK/London

Environmental risk assessment Phases I and II

• Critical evaluation of your data package
• Phase I assessment
• Refining risk assessment
• Phase II assessment Tiers A and B
• What to do if risk assessment gives cause for concern

User safety risk assessment in the EU

• Reviewing toxicology studies
• Setting the scenario
• Risk assessment and management

Pharmacokinetics and bioequivalence

• ADME studies
• Bioequivalence

Workshop - session 2

Day 4 09:00 - 14:45 UK/London

EU and US clinical development

• Dose selection
• Field studies
• VICH guidelines
• Claim-driven approach in the US
• Protocol review and concurrence with CVM
• Value of VICH guidance

EU and US target animal safety

• Pivotal target animal safety studies
• Filed safety studies
• New VICH guideline on TAS

Minor use and minor species (MUMS)

• MUMS approaches in EU and USA
• What are minor uses?
• What are minor species?
• Approaches to preparation of clinical data

Workshop - session 3

Day 5 09:00 - 14:45 UK/London

Workshop - presentations

Pharmaceutical development and the CMC package

• Characterising the active substance
• Formulation development
• Analytical development and setting specifications
• Process scale-up and validation
• Stability studies and shelf life

Managing the USA regulatory submission

• Systems of review at CVM
• Team interaction
• Company and regulator interactions

Writing and managing the EU regulatory submission

• Writing the marketing authorisation application
• Summary of product characteristics and labelling
• Working with writers on detailed and critical summaries in the EU
• Pre-submission advice and oral hearings

For more information about this conference visit https://www.researchandmarkets.com/r/87a8ex

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900